UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

 

For the Month of December 2021

 

Commission File Number: 001-37353

 

BIONDVAX PHARMACEUTICALS LTD.

(Translation of registrant’s name into English)

 

Jerusalem BioPark, 2nd Floor

Hadassah Ein Kerem Campus

Jeusalem, Israel

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F ☒     Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

 

 

 

1

 

 

On December 22, 2021, BiondVax Pharmaceuticals Ltd. issued a press release announcing the execution of definitive agreements for development and commercialization of innovative nanosized COVID-19 antibody therapy with Max Planck Institute of Biophysical Chemistry and University Medical Center Göttingen, Germany. A copy of the press release is filed herewith as Exhibit 99.1.

Exhibit Index

Exhibit No.   Description
     
99.1   Press release, dated December 22, 2021.

 

2

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  BiondVax Pharmaceuticals Ltd.
     
Date: December 22, 2021 By: /s/ Amir Reichman
    Amir Reichman
    Chief Executive Officer

 

 

3

 

 

Biovaxys Technology (QB) (USOTC:BVAXF)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025 Biovaxys Technology (QB) 차트를 더 보려면 여기를 클릭.
Biovaxys Technology (QB) (USOTC:BVAXF)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025 Biovaxys Technology (QB) 차트를 더 보려면 여기를 클릭.